Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 1;34(3):255-260.
doi: 10.1097/MOP.0000000000001131.

Bivalirudin in pediatric extracorporeal membrane oxygenation

Lindsay M Ryerson  1 , Ali B V McMichael  2
Affiliations
Review

Bivalirudin in pediatric extracorporeal membrane oxygenation

Lindsay M Ryerson et al. Curr Opin Pediatr. .

Abstract

Purpose of review: This review summarizes the current literature surrounding the use of bivalirudin as an alternative anticoagulant for pediatric extracorporeal membrane oxygenation (ECMO) patients.

Recent findings: Recent single center studies describe that bivalirudin may be associated with decreased blood product transfusion, decreased cost and similar clinical outcomes for pediatric ECMO patients who have failed unfractionated heparin (UFH) anticoagulation. aPTT is the most common test to monitor bivalirudin but has several limitations. Other tests including dilute thrombin time (dTT) and viscoelastic assays are promising but more study is needed. Current evidence suggests that bivalirudin is a well tolerated and effective alternative anticoagulant for pediatric ECMO patients who have failed UFH anticoagulation but prospective studies are needed to confirm these results.

Summary: Bivalirudin is a promising alternative anticoagulant for pediatric ECMO patients who have failed UFH. Large prospective, multicenter studies are needed to confirm safety and efficacy.

PubMed Disclaimer

References

    1. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004; 17:105–125.
    1. Guy S, Kitchen S, Laidlaw S, et al. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia. Br J Haematol 2008; 142:466–468.
    1. Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother 2005; 6:1349–1371.
    1. Cardinale M, Ha M, Liu MH, Reardon DP. Direct thrombin inhibitor resistance and possible mechanisms. Hosp Pharm 2016; 51:922–927.
    1. Nagle EL, Dager WE, Duby JJ, et al. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med 2013; 14:e182–e188.